abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

このページは 日本語 では利用できません。English で表示されています

記事

2022年6月17日

著者:
Bloomberg

WTO approves partial patent waiver around COVID-19 vaccines

Wikimedia Commons

'WTO approves vaccine-patent waiver to help combat Covid-19 pandemic', 17 June 2022

"The World Trade Organisation (WTO) approved a politically important deal on Friday (June 17) to water down intellectual property restrictions for the manufacture of Covid-19 vaccines after an almost two-year effort involving scores of high-level meetings and much political arm twisting.

During the early morning hours in Geneva, WTO ministers approved a package of agreements that included the vaccine patent waiver, which Director-General Ngozi Okonjo-Iweala previously said was necessary to end the "morally unacceptable" inequity of access to Covid-19 vaccines.

The WTO’s last-minute deal – secured after an all-night negotiating session in Geneva – is an important victory for Dr Okonjo-Iweala, the former head of Gavi – the vaccine alliance – who actively stumped for the accord during her first year as the WTO’s top trade official.

At the same time, the deal delivers a significant blow to vaccine manufacturers such as Pfizer, Moderna and AstraZeneca, which fought hard to prevent nations from undermining the intellectual-property framework that enabled them to produce multiple viable Covid-19 vaccines in record time – saving countless lives...

...India blamed powerful nations for dragging out the negotiations for so long that it finally lost its relevance as pharmaceutical manufacturers were ultimately able to produce an oversupply of vaccines."

プライバシー情報

このサイトでは、クッキーやその他のウェブストレージ技術を使用しています。お客様は、以下の方法でプライバシーに関する選択肢を設定することができます。変更は直ちに反映されます。

ウェブストレージの使用についての詳細は、当社の データ使用およびクッキーに関するポリシーをご覧ください

Strictly necessary storage

ON
OFF

Necessary storage enables core site functionality. This site cannot function without it, so it can only be disabled by changing settings in your browser.

クッキーのアナリティクス

ON
OFF

When you access our website we use Google Analytics to collect information on your visit. Accepting this cookie will allow us to understand more details about your journey, and improve how we surface information. All analytics information is anonymous and we do not use it to identify you. Google provides a Google Analytics opt-out add on for all popular browsers.

Promotional cookies

ON
OFF

We share news and updates on business and human rights through third party platforms, including social media and search engines. These cookies help us to understand the performance of these promotions.

本サイトにおけるお客様のプライバシーに関する選択

このサイトでは、必要なコア機能を超えてお客様の利便性を高めるために、クッキーやその他のウェブストレージ技術を使用しています。